Back to News
research

Amphastar Pharmaceuticals, Inc. (AMPH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Amphastar Pharmaceuticals’ CFO William Peters and SVP Dan Dischner discussed Q4 and fiscal 2025 performance at Barclays’ 2026 healthcare conference, highlighting mixed results across product lines. The company acknowledged underperformance in select Q4 products but emphasized broader fiscal year positives, including revenue growth drivers and operational milestones. Barclays analyst Glen Santangelo led the session, probing financial details and strategic priorities, focusing on balancing successes with shortfalls in recent quarters. Peters framed the discussion around long-term growth despite quarterly volatility, hinting at pipeline developments and market expansion plans without specifying timelines. The dialogue underscored investor interest in Amphastar’s specialty pharma and animal health segments, with analysts seeking clarity on future product performance and financial resilience.
AI Audio Summary
0:00 / 0:00
Click to play
quantum computing images (1).jpg
Quantum News · Media Library

SA Transcripts158.98K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Amphastar Pharmaceuticals, Inc. (AMPH) Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:00 PM EDT Company Participants William Peters - CFO, Executive VP of Finance, Treasurer & DirectorDan Dischner - Senior Vice President of Human Resources & Corporate Communication Conference Call Participants Glen Santangelo - Barclays Bank PLC, Research Division Presentation Glen SantangeloBarclays Bank PLC, Research Division All right. Well, thank you. Good afternoon, everybody. Thank you for joining us. We're very excited to be hosting Amphastar Pharmaceuticals. To my right is Bill Peters, the CFO; and to his right is Dan Dischner, who's in charge of the Corporate Communications and some other things at Amphastar. For those of you who don't know me, I'll introduce myself. I'm Glen Santangelo. I'm the analyst at Barclays that covers the spec pharma and animal health space, among some other things. And we're excited to have you both here today. So thank you for joining us. William PetersCFO, Executive VP of Finance, Treasurer & Director Thank you for having us. Dan DischnerSenior Vice President of Human Resources & Corporate Communication thanks for having us. Question-and-Answer Session Glen SantangeloBarclays Bank PLC, Research Division All right. Well, why don't we just sort of dive right into it. Bill, I think a great place to start is going to be talking about some of the highlights from the fourth quarter and really fiscal '25, maybe more broadly. Obviously, there were some positives in the year that I think we can discuss. But to be balanced, I think maybe even in the fourth quarter, there are a couple of products that maybe fell a little bit short of your expectations. And so why don't you maybe to level set us, just put all that in perspective and then we can sort of dive right in. And as part of that, I don't know there, you can emphasize maybe some

Read Original

Tags

drug-discovery
quantum-investment
quantum-algorithms

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.